Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy

被引：0
作者：
Marcellin, P
Lau, G
Piratvisuth, T
Luo, KX
Bonino, F
Thongasawat, S
Cooksley, G
Hadziyannis, S
Chutaputti, A
Lu, ZM
Fried, M
Chow, WC
Yurdaydin, C
Berg, T
Pluck, N
机构：
[1] Hop Beaujon, Clichy, France
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Songklanakarin Hosp, Songkhla, Thailand
[4] Nangfang Hosp, Guangzhou, Peoples R China
[5] IRCCS Osped Maggiore, Sci Direct, Milan, Italy
[6] Chiang Mai Univ, Chiang Mai 50000, Thailand
[7] Univ Queensland, Royal Brisbane Hosp, Herston, Qld, Australia
[8] H Dynant Hosp, Athens, Greece
[9] Pramongkutklao Hosp, Bangkok, Thailand
[10] Ruijin Hosp, Shanghai, Peoples R China
[11] Univ N Carolina, Chapel Hill, NC USA
[12] Singapore Gen Hosp, Singapore 0316, Singapore
[13] Ankara Univ, TR-06100 Ankara, Turkey
[14] Charite Humboldt Univ Berlin, Berlin, Germany
[15] Roche, Welwyn Garden City, England
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：668A / 668A
页数：1
相关论文
共 50 条
[41]   Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis [J].
Bruno, Savino ;
Shiffman, Mitchell L. ;
Roberts, Stuart K. ;
Gane, Edward J. ;
Messinger, Diethelm ;
Hadziyannis, Stephanos J. ;
Marcellin, Patrick .
HEPATOLOGY, 2010, 51 (02) :388-397
[42]   Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial. [J].
Bronowicki, JP ;
Ouzan, D ;
Tzanck, A ;
Asselah, T ;
Desmorat, H ;
Zarski, JP ;
Foucher, J ;
Bourliere, M ;
Renou, C ;
Tran, A ;
Melin, P ;
Hezode, C ;
Chevallier, M ;
Bouvier, M ;
Lonjon-Domanec, I ;
Pawlotsky, JM .
HEPATOLOGY, 2003, 38 (04) :244A-245A
[43]   Effect of hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks [J].
Rodriguez-Torres, Maribel ;
Govindarajan, Sugantha ;
Shafran, Stephen ;
Morgan, Timothy ;
Anand, Bhupinder S. ;
Barange, Karl ;
Suter, Fredy ;
Lin, Amy ;
Hooper, Gregory ;
Zeuzem, Stefan ;
Shiffman, Mitchell .
HEPATOLOGY, 2006, 44 (04) :333A-333A
[44]   Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy for HBEAG-negative chronic hepatitis B [J].
Marcellin, P ;
Bonino, F ;
Lau, GY ;
Farci, P ;
Yurdaydin, C ;
Piratvisuth, T ;
Jin, R ;
Gurel, S ;
Hadziyannis, S ;
Lu, ZM ;
Popescu, M .
HEPATOLOGY, 2005, 42 (04) :580A-580A
[45]   Peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B:: Results from a large, multinational study. [J].
Lau, G ;
Piratvisuth, T ;
Luo, KX ;
Marcellin, P ;
Thongasawat, S ;
Cooksley, G ;
Gane, E ;
Fried, M ;
Chow, WC ;
Paik, SW ;
Chang, WY ;
Berg, T ;
Flisiak, R ;
Zahm, F ;
Pluck, N .
HEPATOLOGY, 2004, 40 (04) :171A-171A
[46]   PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C [J].
Ideo, G ;
Giuseppe, S ;
Attili, A ;
Chirianni, A ;
Craxi, A ;
Di Perri, G ;
Picciotto, A ;
Rizzetto, M ;
Ruggiero, G ;
Suter, F ;
Sarracino, M .
HEPATOLOGY, 2002, 36 (04) :570A-570A
[47]   Efficacy and tolerability of peginterferon alfa-2a (40kd) and ribavirin in genotype 4 patients with chronic hepatitis C (CHC) under real life conditions [J].
Zehnter, E. ;
Mauss, S. ;
Kaiser, S. ;
Boeker, K. ;
Lutz, T. ;
Heyne, R. ;
John, C. ;
Moog, G. ;
Schober, A. ;
Pfaff, R. ;
Zipf, A. ;
Racky, S. ;
Lohmeyer, J. ;
Bokemeyer, B. ;
Kallinowski, B. ;
Witthoeft, T. ;
Alshuth, U. ;
Hueppe, D. .
JOURNAL OF HEPATOLOGY, 2008, 48 :S316-S316
[48]   Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis [J].
Heathcote, EJ ;
Shiffman, ML ;
Cooksley, WGE ;
Dusheiko, GM ;
Lee, SS ;
Balart, L ;
Reindollar, R ;
Reddy, RK ;
Wright, TL ;
Lin, A ;
Hoffman, J ;
De Pamphilis, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1673-1680
[49]   Efficacy and safety of peginterferon alfa-2a (40KD) and ribavirin in Gt-2/3patients with chronic hepatitis C in a real world setting [J].
Zehnter, Elmar ;
Mauss, Stefan ;
John, Christine ;
Heyne, Renate ;
Moeller, Bernd ;
Lutz, Thomas ;
Bokemeyer, Bernd ;
Kihn, Robert ;
Moog, Gero ;
Vornkahl, Heike ;
Alshuth, Ulrich ;
Hueppe, Dietrich .
GASTROENTEROLOGY, 2006, 130 (04) :A841-A841
[50]   Cost-effectiveness of peginterferon alfa-2a (40KD) (PEGASYS®) compared to lamivudine as first line treatment of chronic hepatitis B (CHB) in the UK [J].
Veenstra, DL ;
Sullivan, SD ;
Dusheiko, GM ;
Jacobs, M ;
Lewis, GJ ;
Patel, KK .
VALUE IN HEALTH, 2005, 8 (06) :A120-A120
12345